Company*
(Country; Symbol)

Company*
(Country; Symbol)

Product

Terms/Details (Date)


Albany
Molecular
Research
Inc.
(AMRI)

Seattle Genetics Inc. (SGEN)

Preferred provider agreement for the manufacture of Seattle Genetics' drug-linker system

The deal secures rights for Seattle Genetics' licensees to work directly with AMRI on the manufacturing of drug-linker units; terms were not disclosed (7/13)

Amgen Inc.
(AMGN)

NPS Pharmaceuticals Inc. (NPSP)

NPS will promote Amgen's Kineret, a biologic therapy for rheumatoid arthritis, in the U.S.

Amgen will supply product and support, and NPS will get a percentage of Kineret revenues; NPS will be the exclusive representative to rheumatologists (8/9)

Arcturus
Bioscience Inc.*

Paradigm Genetics Inc. (PDGM)

Paradigm Array Laboratories began offering services using Arcturus technology

The technology involves microgenomics and laser-capture microdissection; terms were not disclosed (8/11)

BioDiscovery Inc.*

Bio-Rad Laboratories Inc. (AMEX:BIO)

BioDiscovery software and its data analysis package will be incorporated into Bio-Rad microarray products

Bio-Rad will sell the products with its microarray scanner and arrayer equipment worldwide; terms were not disclosed (6/29)

Cepheid
Inc.
(CPHD)

Gene Co.* (Hong Kong)

Nonexclusive, three-year deal under which Gene Co. will distribute Cepheid's products in China and Hong Kong

The products include SmartCycler Systems, accessories and OmniMix HS reagents; terms were not disclosed (7/13)

CMC
Biopharmaceuticals
A/S*
(Denmark)

Resistentia AB* (Sweden)

Development and manufacturing deal for a fusion protein for use in IgE-mediated allergies

CMC will manufacture the product at its facility in Copenhagen; terms were not disclosed (9/15)

Large Scale
Biology Corp.
(LSBC)

Planet Biotechnology Inc.*

Deal to extract and purify Planet's CaroRx, a plant-made antibody to control dental caries

Terms of the manufacturing agreement were not disclosed; the product has completed Phase I trials (7/15)

LION Bioscience
AG
(Germany; LEON)

BioByte Corp.* and ChemNavigator Inc.*

LION will incorporate Bio-Byte's calculation software into its LeadNavigator software

ChemNavigator is providing software modules for integration into LeadNavigator; LION also agreed to resell ChemNavigator products and services; terms of the deals were not disclosed (8/24)

Nonlinear
Dynamics Ltd.*
(UK)

Matrix Science Ltd.* (UK)

Deal to develop integrated proteomics software products

Nonlinear's protein informatics system will be integrated with Matrix's Mascot Server search engine; terms were not disclosed (8/9)

Perlegen
Sciences Inc.*

Affymetrix Inc. (AFFX)

Deal to provide researchers access to custom genotyping services via Perlegen's high-throughput genotyping facility

Affymetrix will market the service, which Perlegen will provide on a fee-for-service basis (7/6)

Qiagen NV
(the Netherlands;
QGENF)

Evotec OAI AG (Germany; FSE:EVT)

They agreed to promote the benefits of combining Qiagen's TOM-amidites RNAi products with Evotec's Opera platform

The collaboration with Evotec's subsidiary, Evotec Technologies GmbH, is focused on providing functional gene analysis; terms were not disclosed (9/13)

Rentschler
Biotechnologie GmbH
(Germany; part of the
Rentschler Group)

Maxygen Inc. (MAXY)

Deal for the scale-up and manufacture of Phase I and Phase II supplies for a Maxygen program

The product is Maxygen's next-generation granulocyte-cell stimulating factor molecule; terms were not disclosed (9/9)

Sirna
Therapeutics
Inc.
(RNAI)

Archemix Corp.*

Four-year development and manufacturing alliance for all of Archemix's cGMP aptamers through Phase IIa trials

Archemix also got a nonexclusive license to relevant intellectual property; the deal followed an October 2003 agreement under which Sirna manufactured an anti-thrombin aptamer (7/28)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange, TSE = Toronto Stock Exchange.

No Comments